8-K: GRI Bio's IPF Drug GRI-0621 Demonstrates Encouraging Safety in Phase 2a Interim Analysis, Study to Continue

GRI Bio, Inc. announced positive 6-week interim safety results for its lead drug candidate, GRI-0621, in an ongoing Phase 2a study for idiopathic pulmonary fibrosis (IPF), with the Independent Data Monitoring Committee recommending the study continue as planned due to no safety concerns.

Summary

• GRI Bio reported positive 6-week interim safety results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
• The Independent Data Monitoring Committee (IDMC) confirmed no safety concerns in the first 24 patients evaluated after 6 weeks of treatment with GRI-0621.
• GRI-0621, administered at 4.5mg orally once daily, was found to be safe and well-tolerated.
• No adverse events associated with hyperlipidemia (as assessed by LDL, HDL, and triglyceride levels) were observed in the 24 patients.
• There were no clinically meaningful changes in HDL, LDL, or TG levels, consistent with earlier 2-week safety data, and all subjects remained within protocol-accepted ranges.
• The IDMC recommended that the study should continue as planned.
• The company expects to report 6-week interim biomarker data for the 24 patients in July 2025.
• Topline data from the Phase 2a biomarker study is anticipated in the third quarter of 2025.
• The Phase 2a study is a randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study enrolling approximately 36 subjects with IPF, randomized in a 2:1 ratio for GRI-0621 vs. placebo for 12 weeks.
• A sub-study is concurrently examining the number and activity of NKT cells in bronchoalveolar lavage (BAL) fluid for up to 12 eligible subjects.

Sentiment

Score: 8

Explanation: The interim safety results for GRI-0621 are positive, with the Independent Data Monitoring Committee recommending the continuation of the Phase 2a study due to no safety concerns. This is a crucial step forward for the drug candidate in a disease area with significant unmet medical need, and the company remains on track for further data releases.

Positives

• GRI-0621 demonstrated encouraging safety results at the 6-week interim analysis in the Phase 2a study for Idiopathic Pulmonary Fibrosis (IPF).
• The Independent Data Monitoring Committee (IDMC) recommended continuing the study as planned, indicating no safety concerns were demonstrated in the data reviewed.
• GRI-0621 was found to be safe and well-tolerated in the first 24 patients evaluated per protocol.
• No adverse events associated with hyperlipidemia (LDL, HDL, and triglyceride levels) were observed in the 24 patients assessed at the 6-week visit.
• No clinically meaningful changes in HDL, LDL, or TG levels were reported, consistent with previous 2-week safety data, and all subjects remained within protocol-accepted ranges.
• The interim results show that GRI-0621's receptor selectivity is consistent with the toxicity profile observed in earlier studies evaluating oral tazarotene in over 1,700 patients treated for up to 52 weeks.
• The company remains on track to report 6-week interim biomarker data in July 2025 and topline data in Q3 2025.

Risks

• The inability to maintain the listing of the Company's common stock on The Nasdaq Capital Market and to comply with applicable listing requirements.
• Changes in applicable laws or regulations.
• The inability of the Company to raise financing in the future.
• Uncertainty regarding the success, cost, and timing of the Company's product development activities.
• The inability of the Company to obtain and maintain regulatory clearance or approval for its respective product candidates, and any related restrictions and limitations of any cleared or approved product candidates.
• The inability of the Company to identify, in-license or acquire additional technology.
• The inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing.
• Uncertainty regarding the size and growth potential of the markets for the Company's products and services, and their respective ability to serve those markets, either alone or in partnership with others.
• The failure to achieve any milestones or receive any milestone payments under any agreements.
• Inaccuracy in the Company's estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing.
• The Company's ability to protect and enforce its intellectual property portfolio, including any newly issued patents.
• The interim data discussed may not be indicative of later or final data for this trial, and additional study and favorable results will be needed for development of GRI-0621 to continue.

Future Outlook

The company expects to report 6-week interim biomarker data in July 2025 and topline data from the Phase 2a biomarker study in the third quarter of 2025. The Independent Data Monitoring Committee has recommended continuing the study as planned, indicating progression of the clinical trial.

Management Comments

• "We are happy to report the IDMC confirmed no safety concerns in the first 24 subjects evaluated after 6-weeks of treatment, building upon the 2-week safety data reported earlier and adding to the large safety data available for oral tazarotene." Marc Hertz, PhD, Chief Executive Officer of GRI Bio.
• "We are encouraged by the consistent safety data and early anti-fibrotic trends previously reported and remain on track to report 6-week interim biomarker data in the coming weeks followed by topline data expected in the third quarter of this year." Marc Hertz, PhD, Chief Executive Officer of GRI Bio.

Industry Context

Currently available treatments for Idiopathic Pulmonary Fibrosis (IPF) are limited to only two approved drugs, which are associated with significant side-effects, limited patient compliance, and no impact on survival. GRI Bio's GRI-0621 aims to address this significant unmet medical need by targeting Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade.

Comparison to Industry Standards

• Currently available treatments for IPF are limited to only two approved drugs, highlighting a significant unmet medical need that GRI-0621 aims to address.
• These existing treatments are noted to come with significant side-effects, limited patient compliance, and no impact on survival, suggesting GRI-0621 could offer a potentially improved therapeutic profile.
• The safety profile of GRI-0621 is consistent with the toxicity profile observed in earlier studies evaluating oral tazarotene in over 1,700 patients treated for up to 52 weeks, providing a large historical safety dataset for comparison.

Stakeholder Impact

• Shareholders: Positive safety data and the continuation of the clinical trial could enhance investor confidence and potentially lead to an increase in the company's share price, as it de-risks the drug development process.
• Patients (IPF): Successful development of GRI-0621 could offer a new, potentially safer and more tolerable treatment option for Idiopathic Pulmonary Fibrosis, addressing a significant unmet medical need.
• Employees: Continued progress in the clinical pipeline supports job security and potential growth opportunities within GRI Bio.

Next Steps

• Report 6-week interim biomarker data (n=24) from the Phase 2a study in July 2025.
• Report topline data from the Phase 2a biomarker study in Q3 2025.
• Continue the Phase 2a study as planned, enrolling approximately 36 subjects with IPF.

Key Dates

Recommendation

Keywords

GRI Bio, GRI-0621, Idiopathic Pulmonary Fibrosis, IPF, Phase 2a study, clinical trial, safety results, NKT cell modulators, biotechnology, RARdual agonist, fibrotic diseases, autoimmune diseases, drug development, biopharmaceutical